Supplementary Tables 1 - 5, Figures 1 - 6 from Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children

Abstract

<p>PDF file - 685K, Supplementary Table S1. Summary of the pediatric MB patients included in the study Discovery cohort. Supplementary Table S2. Summary of the pediatric MB patients included in the study Validation cohort. Supplementary Table S3. PAM class prediction validation for MB subgroup assignment of Discovery cohort and cultured cells. Supplementary Table S4. PAM class prediction validation for MB subgroup assignment of Validation cohort. Supplementary Table S5. Univariate and multivariate analyses of clinical, pathological and biological endpoints in the Validation cohort. Supplementary Figure S1. MB survival in Validation cohort is stratified by molecular subtype. Supplementary Figure S2. PLK1 is invariably expressed between patient cohorts and between MB subgroups. Supplementary Figure S3. BI2536 sensitivity depends on PLK1 expression in primary MB cells. Supplementary Figure S4. MB cells lines expressing PLK1 experience cell cycle arrest and reduced proliferation with PLK1 inhibition. Supplementary Figure S5. MB cell PLK1 inhibition morphology using immunofluorescence. Supplementary Figure S6. MB cell lines treated with anti-cancer drugs.</p>